停牌！600721，拟易主

Core Viewpoint - Baihua Pharmaceutical is undergoing a potential change in control as its major shareholders are planning to transfer shares, leading to a suspension of trading starting December 29, 2023 [1][4]. Group 1: Shareholder Changes - The major shareholders, Mi Zaiqi, Mi Enhua, and Yang Xiaoling, are in the process of planning a share transfer that may result in a change of control of the company [1]. - The company will be suspended from trading for no more than two trading days starting December 29, 2023, with a closing price of 12.24 yuan per share and a market capitalization of 4.707 billion yuan as of December 26, 2023 [4]. - As of December 1, 2025, the shareholders confirmed the termination of their joint action agreement, which will automatically dissolve their unified action relationship [7]. Group 2: Shareholding Structure - Mi Zaiqi, Mi Enhua, and Yang Xiaoling collectively hold 20.68% of Baihua Pharmaceutical's shares, with individual holdings of 8.99%, 6.70%, and 4.99% respectively [9]. - Li Jiancheng, previously a joint action partner, no longer holds a controlling interest in the company, and his shares will not be included in the combined calculation [8]. Group 3: Financial Performance - Baihua Pharmaceutical has experienced significant fluctuations in its net profit since the change in control in 2019, with net profits recorded as 34.38 million yuan, -320 million yuan, 59.83 million yuan, -34.76 million yuan, 12.97 million yuan, and 41.48 million yuan from 2019 to 2024 [9]. - For the first three quarters of 2025, the company's net profit attributable to shareholders increased by 36.41% year-on-year, reaching 32.67 million yuan, attributed to improved project management and cost control [11]. - The total revenue for the current reporting period is 96.52 million yuan, reflecting a year-on-year increase of 2.32% [11].